Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment

Narendiran Rajasekaran1 Division of Oncology, Stanford School of Medicine, Stanford University, Stanford, CA, USA;1 Division of Oncology, Stanford School of Medicine, Stanford University, Stanford, CA, USA

Cariad Chester1 Division of Oncology, Stanford School of Medicine, Stanford University, Stanford, CA, USA;1 Division of Oncology, Stanford School of Medicine, Stanford University, Stanford, CA, USA

Atsushi Yonezawa1 Division of Oncology, Stanford School of Medicine, Stanford University, Stanford, CA, USA;2 Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan

Xing Zhao1 Division of Oncology, Stanford School of Medicine, Stanford University, Stanford, CA, USA;3 Tissue Engineering and Stem Cells Research Center, Department of Immunology, Guiyang Medical University, Guiyang, Guizhou Province, People’s Republic of China

Holbrook E Kohrt1 Division of Oncology, Stanford School of Medicine, Stanford University, Stanford, CA, USACorrespondence[email protected]

Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment

Table 1 List of antibodies mentioned in the review

Table 2 Ongoing active clinical trials with reovirus

Table 3 A list of therapeutic reagents mentioned in the article in clinical trials

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment

Figures & data

Table 1 List of antibodies mentioned in the review

Table 2 Ongoing active clinical trials with reovirus

Table 3 A list of therapeutic reagents mentioned in the article in clinical trials

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date